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The age at onset refers to the time period at which an individual experiences the first symptoms of a disease. In autoimmune
diseases (ADs), these symptoms can be subtle but are very relevant for diagnosis. They can appear during childhood, adulthood
or late in life and may vary depending on the age at onset. Variables like mortality and morbidity and the role of genes will be
reviewed with a focus on the major autoimmune disorders, namely, systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA), multiple sclerosis (MS), type 1 diabetes mellitus (T1D), Sjo¨gren’s syndrome, and autoimmune thyroiditis (AITD). Early age
at onset is a worst prognostic factor for some ADs (i.e., SLE and T1D), while for others it does not have a significant influence on
the course of disease (i.e., SS) or no unanimous consensus exists (i.e., RA and MS).
1. Introduction
Autoimmune diseases (ADs) aﬀect approximately 5% of the
world population [1, 2]. The age at onset varies widely
depending on the disease. For example, sixty-five percent
of patients with systemic lupus erythematosus (SLE) start
manifesting their symptoms between ages 16 and 55 [3].
Another 20 percent manifest them before age 16 and the
remaining 15 percent after age 55 [4]. Rheumatoid arthritis
(RA) can begin at any age but has its peak between ages 30
and 55 [5]. Juvenile idiopathic arthritis (JIA) is a term used
to describe the autoimmune, inflammatory joint condition
that develops in children. Another prevalent AD is Sjo¨gren’s
syndrome (SS) which is considered to be more prevalent
in women between ages 45 and 50 [6]. Multiple Sclerosis
(MS) usually appears between ages 20 and 40, and it is very
rare during adolescence [7]. Type 1 diabetes mellitus (T1D)
is considered a childhood and adolescent disease with two
peaks of onset, one between ages 5 and 9 and a second
between ages 10 and 14 [8]. On the other hand, an adult
onset would be considered to be in a range of 25–61 years old
[9]. Finally, autoimmune thyroiditis (AITD) is thought to be
a disease that can appear in childhood but is more prevalent
during adulthood [10]. Herein, we analytically reviewed the
eﬀect of age at onset on the most prevalent ADs, their clinical
diﬀerences (Table 1), and their genetic and immunologic
relationships (Table 2).
2. Systemic Lupus Erythematosus
SLE is a chronic AD that aﬀects individuals of every age.
It is more common in adults, but it may be diagnosed
during childhood as well [11]. Childhood disease onset is
characterized by a high degree of morbidity compared with
adult SLE populations [12]. It is associated with a higher
mean in the Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) scores at presentation. The patients have a
higher frequency of renal disease, malar rashes, pericarditis,
hepatosplenomegaly, and hematologic alterations [13]. In
treatment, they usually have a higher use of prednisone and
the need for additional immunosuppressive therapies [14].
Patients at this age are susceptible to a longer lifetime of
damage from the disease flares and the treatment side eﬀects
and a mortality rate that is 2 times higher [11, 12]. Other
associations found in childhood onset are growth failure,
delayed puberty, and fibromyalgia. In contrast, adult onset
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Table 1: Clinical diﬀerences between early and adult onset.
AD Early onset Late onset
SLE
Higher degree of morbidity [12]
Higher (SLEDAI) score at presentation
Higher incidence of renal disease
Malar rashes
Pericarditis
Hepatosplenomegaly
Hematologic alterations (Leucopenia)
Higher use of prednisone
Additional immunosuppressive therapies
Greater lifetime of damages from the disease
flares and the treatment side eﬀects [13]
2 times higher mortality rate
Growth failure
Delayed puberty
Fibromyalgia [11]
Higher odds of presenting proteinuria
Haemolytic anaemia
Arthritis [16]
Increased rate of pulmonary
disease [11]
Increased rate of simultaneously
developing another AD [12]
RA
Proximal Interphalangeal,
metacarpophalangeal, elbow,
metatarsophalangeal, and ankle joints
Classical rheumatoid hand deformities
Interstitial lung disease
Associated SS [21]
Shorter morning stiﬀness [19]
Acute onset in large and small
joints (specially shoulders)
PMR-like symptoms [20]
Constitutional features
Weight loss
Myalgia
Rheumatic nodules
Neuropathy [21]
Longer morning stiﬀness [19]
Positive RF PJIA∗
Rapid onset of inflammation in
multiple joints
Proximal interphalangeal,
metacarpophalangeal, elbow,
metatarsophalangeal, and ankle
joints
Eﬀects of the disease in a
growing skeleton:
Growth retardation
Accelerated growth of an aﬀected
joint [24]
SS Recurrent parotid gland enlargement
Milder extraglandular manifestations [32]
Sicca symptoms [31]
T1D Ketosis and ketoacidosis
Higher mean glycated hemoglobin [38, 40]
Better preserved B-cell function
Longer symptomatic period
before diagnosis
Less frequency of insulin
autoantibodies and HLA class II
susceptibility alleles [40, 41]
Milder signs of metabolic
decompensation and a lower
glycated hemoglobin level at
diagnosis [39, 42]
MS
Mainly relapsing remitting disease onset
Frequent presentation with
brainstem-cerebellar dysfunction
Pyramidal symptom
Optic neuritis [52]
Primary progressive course
Motor symptoms are
predominant
AITD
Often transient [10]
Delayed growth
Bradykinesia
Delayed pubertal development [57, 58]
Permanent [10]
AD: autoimmune disease; RA: rheumatoid arthritis; SS: Sjo¨gren’s syndrome; T1D: type 1 diabetes; MS: multiple sclerosis; AITD: autoimmune
thyroiditis; PJIA: polyarticular juvenile idiopathic arthritis; RF: rheumatoid factor.
∗In RA, early age at onset is considered ≥16 years old. Positive RF PJIA is considered a comparable disease with a childhood onset (<16 years old).
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Table 2: Genetic and immunological factors related to age at onset.
Autoimmune disease Population Immunologic Genetic
SLE early onset∗ African Americans and Gullah
Odds of developing the disease
increased by 48% per risk allele in
Gullah patients and 25% in
African-American patients [16]
Caucasians Hispanics African
Americans and Gullah
Higher odds of presenting
Anti-dsDNA antibody [16]
Caucasians Association with MBL2 gene [17]
Positive RF PJIA Caucasians
Higher frequency of Anti-CCP
antibodies
HLA-DR4 alleles [26]
RA early onset Hispanics
Higher frequency of Anti-CCP
antibodies
HLA-DRB1 DERAA sequence [29]
SS early onset Asians
Higher prevalence of anti-M3R
Antibodies [35]
T1D early Onset
Caucasians
Association with high Risk HLA
DQB1∗02/∗0302 [44]
Association with PTPN22 C1858T
[45]
African Americans
Association with absence of
DQB1∗0602 and increase in
DQB1∗0201 [42]
Asians
Association with STAT4
polymorphism [46]
T1D late onset Caucasians
Less frequency of insulin
autoantibodies
MS susceptibility Hispanics
High risk DQB1∗0602 susceptibility
allele is the same that protects in
T1D [55]
AITD early onset Asians
Coexistence of HLA-B∗46 and
HLA-Cw∗01 [60]
AD: autoimmune disease; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: Sjo¨gren’s syndrome; M3R: muscarinic 3 receptor; T1D: type 1
diabetes; MS: multiple sclerosis; AITD: autoimmune thyroiditis; PJIA: polyarticular juvenile idiopathic arthritis; RF: rheumatoid factor.
∗Defined as ≤20 years old.
patients are more likely to develop pulmonary disease [11]
and may have an increased rate of simultaneously developing
another AD such as SS [15]. Additionally, Webb et al.
showed that childhood onset had higher odds of presenting
proteinuria, haemolytic anaemia, arthritis, leucopenia, and
anti-dsDNA antibody. They also showed that early adult
onset (≤50 years) had greater odds of having proteinuria, cel-
lular casts, seizures, anti-nRNP antibody, anti-Sm antibody,
and anti-dsDNA antibody than late-adult-onset patients
(>50 years) [16]. Hersh et al. stated that rates for clotting
disorders, myocardial infarction, and neurological disorders
(e.g., seizures) are similar in both of them [11]. In both cases,
better disease outcome can be achieved if an early diagnosis
is made by a better recognition of age-specific manifestations
and the use of a good treatment algorithm [15].
As other ADs, SLE is a complex disease in which several
polymorphic genes and environmental factors over time
influence the onset and course of disease. Among the genes
found to be associated with SLE, MBL2 gene has been
suggested to influence the age at onset [17]. Webb et al.
showed that odds of developing SLE during childhood
(<18 years) increased by 48% per risk allele in Gullah
people with SLE and 25% in African-American patients. No
association between the number of SLE risk alleles and age
at onset in Hispanic patients and European American was
found [16].
3. Rheumatoid Arthritis and Juvenile
Idiopathic Arthritis
RA is a chronic, systemic, and destructive inflammatory AD
that involves both small and large diarthrodial joints. It usu-
ally develops in middle-aged adults but may also appear dur-
ing childhood or late in life [18]. Patients who are diagnosed
between ages 16 and 65 are considered young onset and after
65, late onset with each of them having diﬀerent semiologic
characteristics. Pease et al. found that late-onset patients had
longer stiﬀness in the morning [19]. In contrast, Deal et al.
reported no diﬀerence in morning stiﬀness between young-
and late-onset patients [5]. It has been reported that older
patients have more acute onset in both large (specially the
shoulders) and small joints and usually present polymyalgia
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rheumatica-like symptoms [20]. Turkcapar et al. reported
that proximal interphalangeal, metacarpophalangeal, elbow,
metatarsophalangeal, and ankle joints are more associated
with young-onset AR. Classical hand deformities, interstitial
lung disease, and SS presented less commonly at late onset.
However, these patients can present more constitutional
features like weight loss, myalgia, rheumatic nodules, and
neuropathy [21]. Anti-CCP seropositivity and elevated
inflammatory markers at onset are associated with poor
radiological outcome in both early and late onset [22, 23].
Studies diﬀer when talking about prognosis and report
favorable, similar, or worse outcome. Most of them conclude
that treatment should be instituted equally on both.
Juvenile idiopathic arthritis (JIA) is a term that describes
a group of disorders that share the clinical manifestation
of chronic joint inflammation from unknown causes that
begins before 16 years of age [24]. It is divided into seven
groups being polyarticular JIA (PJIA), the one most similar
to RA and the most related to rheumatoid factor positivity
[25]. PJIA is defined by the presence of more than four
aﬀected joints during the first six months of illness. There is a
bimodal distribution of the age at onset: from 2 to 5 years and
10 to 14. Children with polyarticular disease with onset after
10 years of age are divided into negative rheumatoid factor
(RF) polyarthritis and positive RF polyarthritis. Positive RF
polyarthritis tends to be associated with anti-CCP antibodies
and a more severe disease than their adult counterpart
[26]. They usually have a rapid onset of inflammation in
multiple joints, especially hands, wrists, elbows, and feet. A
big diﬀerence between it and the adult form of the disease
is the eﬀect of the disease on their growing skeleton that
can lead to growth retardation or accelerated growth of an
aﬀected joint [24].
The HLA-DRB1 gene has been associated with RA sus-
ceptibility, especially with those alleles carrying the shared
epitope [27]. Anti-CCP antibodies can be detected at
early disease stages and may be used as indicators of RA
progression and prognosis [28]. Diaz et al. reported that
anti-CCP antibodies and the HLA-DRB1 DERAA sequence
influence the age at onset of RA [29]. This finding may be
useful to predict early RA onset in genetically predisposed
patients [29]. In JIA, RF-positive polyarthritis with anti-
CCP antibodies is associated with the presence of HLA–DR4
alleles and an aggressive disease course [26].
4. Sjo¨gren’s Syndrome
SS is a chronic AD characterized by xerophthalmia and xeros-
tomia caused by a progressive lymphocytic and plasma cell
infiltration in the exocrine glands andmay also have systemic
involvement. It is very rare during childhood [30]. Drosos
et al. showed that recurrent parotid gland enlargement was
more common in early age onset while sicca symptoms were
more common in adults [31]. Ostuni et al. reported that
the clinical manifestations were similar but extraglandular
manifestations were milder [32]. Anaya et al. implied that the
clinical symptoms in children do not fulfill the classical diag-
nostic criteria which are successfully applied to adults [33].
Botsios et al. found that young, adult and elderly patients
had similar sensitivity of diagnostic test positivity [34]. In
contrast, Nakamura et al. showed the prevalence of anti-
muscarinic 3 receptor (anti-M3R) antibodies is higher in
early-onset SS than in late-onset SS patients [35]. However,
this findings warrant further replication and confirmation.
HLA-DRB1∗0301-DQB1∗0201 haplotype has been asso-
ciated with SS [36]. No age at onset relationship was found.
5. Type 1 Diabetes
T1D is a chronic AD resulting from progressive destruction
of the pancreatic B cells. B-cell damage may be induced
at any age [37]. Childhood- and late-onset patients are
characterized by symptoms like polydipsia, polyuria, and
weight loss, but younger patients suﬀer more from diabetic
ketoacidosis and ketosis as the initial presentation [38, 39].
Studies indicate that late-onset patients have better preserved
B-cell function than early-onset patients. They are also char-
acterized by a longer symptomatic period before diagnosis
and a lower frequency of insulin autoantibodies and HLA
class II susceptibility alleles [40, 41]. Adult onset can be
associated with milder signs of metabolic decompensation
and a lower glycated hemoglobin level at diagnosis [39, 42].
Associated HLA-Class II alleles for development of
the disease are identified. DRB1∗0301-DQA1∗0501-
DQB1∗0201 is considered risk alleles and DRB1∗1301-
DQB1∗0603-DQB1∗0602, protective alleles [43]. The high-
risk HLA DRB1∗0301 and DQB1∗02/∗0302 alleles
are commonly associated with young onset as well as absence
of DQB1∗0602. Adult patients carry high-risk DQB1∗02/
0302 less frequently [39, 42, 44]. The PTPN22 C1858T
polymorphism has also been associated with higher risk
for development of ADs, specifically T1D, RA, SLE, and
Graves disease. This polymorphism could be associated with
development of T1D at an early age [45]. Lee et al. showed
that STAT4 polymorphism is associated with early-onset
T1D and not with late onset in Asian population and also
suggested a dosage eﬀect of risk alleles on the age of onset of
disease [46].
6. Multiple Sclerosis
Age at onset of MS as in most of ADs is defined as the age
when the first symptoms appear, although the disease process
may have begun earlier [47]. Duquette et al. reported an
early-onset prevalence of 2.7% with respect to the entire MS
population [48]. Studies are consistent with the idea that, in
early onset, mild and severe disability levels are reached after
a longer time than in the case of adult onset. However, these
disability levels are also reached at a lower age in comparison
with adult cases. This can be translated into more disabil-
ity in early-onset patients than their corresponding adult
counterpart at the same age. Bad prognostic factors for a
worse outcome include disability in the first year, high relapse
rate, short interattack intervals, the relapsing progressive
course, or a shift of the progressive phase [7, 49–51]. Deryck
et al. showed specific clinical characteristics in patients
with early onset such as mainly relapsing remitting disease
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onset and frequent presentation with brainstem-cerebellar
dysfunction, pyramidal symptom, and optic neuritis [52].
Kis et al. showed that primary progressive course and motor
symptoms are more characteristic of late-onset patients [53].
Trojano et al. state that current age, together with duration of
disease and apart from age at onset, influences MS progres-
sion [54].
Associated HLA-class alleles of the disease are also identi-
fied. DRB1∗1501 andDQB1∗0602 were found to be high risk
factors for MS [55]. No onset relationship was described, but
high risk factor allele DQB1∗0602 is thought to be protective
in T1D.
7. Autoimmune Thyroiditis
AITD is an inflammatory state of the thyroid gland that
results from interaction between genetic and environmental
factors. Hashimoto thyroiditis is the most frequent form of
chronic autoimmune thyroiditis. This is the most common
cause of hypothyroidism in children [56]. Some of its mani-
festations at this age are eﬀects on growth, bad school perfor-
mance, bradykinesia, and delayed pubertal development. A
goiter is themain symptom that indicates AITD. Patients that
receive proper treatment at this age will probably experience
normal growth and puberty [57, 58]. Both young and adult
onset patients may show symptoms of lethargy, intolerance
to cold, constipation, dry skin, brittle hair, and muscle pain.
Late-onset hypothyroidism, once it begins, is permanent but,
in some young onset patients and postpartum women, it is
often transient [10]. Young patients with other ADs are at
increased risk of having AITD. A good example is T1D. Riley
et al. showed that approximately 20 percent of T1D patients
have high serum antithyroid antibody concentrations and 5
percent have abnormalities in thyroid function [59]. That is
why they have to be screened annually.
Genetic susceptibility is linked to the HLA DR3 group
[57] and to polymorphisms at CTLA-4 gene, among others.
Cho et al. suggested that coexistence of HLA-B∗46 and HLA-
Cw∗01 may be a genetic marker for early-onset AITD in
Koreans [60].
8. Conclusions
Age at onset varies among ADs and so do their manifesta-
tions. Some of them, for example, MS and SS, are rare during
childhood but others such as T1D primarily occur during
this period. Early age at onset cannot always be associated
with a worse prognosis. Early age at onset is a worst
prognostic factor for some ADs (i.e., SLE and T1D), while for
others it does not have a significant influence on the course
of disease (i.e., SS) or no unanimous consensus exists (i.e.,
RA and MS). Knowledge of the early-age symptoms will help
physicians to provide better treatment which, coupled with
educational and transition support, might improve outcome.
Understanding of genetic influences and association studies
between diseases are required to determine the role of genes
in age at onset. Studies with a larger number of people with
nontypical ages at onset would bring further insights.
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